Valneva Shares Soar to Highest Since May as EMA Validates Key Lyme Vaccine Filing

3-line summary

• Valneva shares soared to their highest level since May after the European Medicines Agency validated a key filing for its Lyme disease vaccine, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.